Libo Bio raises $15M Series A for RNA-targeting small molecules
What's the deal? Libo Bio, a Hangzhou-based developer of RNA-targeting small-molecule drugs, has raised US$13.8M in a Series A round. Loyal Valley CapitalDealroom has a profile for this one. Try Dealroom →, Sinovation Ventures, and CICC Capital co-led, with Yuansheng Venture CapitalDealroom has a profile for this one. Try Dealroom → participating.
What does it do? Founded in 2022, Libo Bio focuses on AI-enabled target discovery and the development and optimisation of RNA-targeting small molecules through a combined dry- and wet-lab approach.
Where's the money going? The company plans to use the funds to advance several RNA-targeting drug candidates through preclinical research and to upgrade its technology platform.
Why it matters: The round drew a notably deep investor bench for an early-stage biotech, signalling continued appetite for the RNA-targeting small-molecule approach. The raise follows a near-100-million-CNY Pre-A round in 2025, suggesting investors remain willing to fund this early technical path.
What could go wrong? Libo Bio sits at a critical point in clinical translation, and funding alone does not prove its platform yields clinical value. The key test is whether it can push lead candidates to an investigational new drug (IND) filing and disclose verifiable data.
The signal: More mature benchmarks already exist — US-based Rgenta Therapeutics has advanced an RNA-targeting small-molecule candidate into late-stage clinical development, underscoring the gap between a discovery platform and clinical validation. For Libo Bio, the round's real significance will hinge on IND progress, clinical data, and the specific milestones it funds.
Read more: sohu.com
Image credit: Generated with Gemini
